Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04343261 · ClinicalTrials.gov registry record · Phase 2
Convalescent Plasma in the Treatment of COVID 19
A Phase 2 study of Coronavirus and COVID, sponsored by Trinity Health Of New England.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT04343261 is a Phase 2 study of Coronavirus and COVID that has completed, run by Trinity Health Of New England. The registered enrollment target is 48 participants, below the 1,403-participant average among 20 other Coronavirus trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04343261, a Phase 2 study of Coronavirus and COVID, has completed, sponsored by Trinity Health Of New England.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.
Conditions Studied
Interventions
- BIOLOGICAL Convalescent Plasma
Study Locations (1)
Connecticut
- Trinity Health Of New England - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-04-10 |
| Est. Completion | 2020-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04343261
The ClinicalTrials.gov registry entry for NCT04343261 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,403-participant average among 20 other Coronavirus trials with a reported enrollment target (97% lower). The listed sponsor is Trinity Health Of New England, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Coronavirus appearing as the primary indexed condition, and to 1 intervention - of which Convalescent Plasma is the first listed.
NCT04343261 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT04343261 about?
NCT04343261 is a clinical study titled "Convalescent Plasma in the Treatment of COVID 19". The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.
What is the current status of trial NCT04343261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-04-10. Estimated completion is 2020-08-13.
What conditions does trial NCT04343261 study?
This clinical trial studies the following conditions: Coronavirus, COVID, Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2).
What interventions are being tested in trial NCT04343261?
The interventions under investigation include: Convalescent Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04343261?
This trial is sponsored by Trinity Health Of New England, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04343261 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronavirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
COMPLETED · Phase 2
-
Convalescent Plasma to Stem Coronavirus (CSSC-001)
COMPLETED · Phase 2
-
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
COMPLETED · Phase 2
-
University of Utah COVID-19 Hydrochloroquine Trial
COMPLETED · Phase 2
-
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
RECRUITING
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.